GLAXOSMITHKLINE and Pfizer
have confirmed the completion
of a transaction which has seen
the transfer of GSK’s meningitis
vaccines Nimenrix and Mencevax
to Pfizer.
The vaccines were acquired by
Pfizer Ireland Pharmaceuticals
effective 01 Oct, with GSK divesting
the products in order to satisfy
regulatory clearances as part of
its three-part transaction with
Novartis, under which GSK acquired
Novartis’ global vaccines business
including Menveo and Bexsero.
Effective immediately Pfizer is
responsible for the marketing
and promotion of Nimenrix and
Mencevax, but for a transition
period GSK will continue to manage
all pharmacovigilance activities,
medical information inquiries and
product complaints.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.